These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 18941346)

  • 1. Altered nonrenal drug clearance in ESRD.
    Nolin TD
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):555-9. PubMed ID: 18941346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of chronic renal failure on drug metabolism and transport.
    Dreisbach AW
    Clin Pharmacol Ther; 2009 Nov; 86(5):553-6. PubMed ID: 19776735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonrenal drug clearance in CKD: Searching for the path less traveled.
    Momper JD; Venkataramanan R; Nolin TD
    Adv Chronic Kidney Dis; 2010 Sep; 17(5):384-91. PubMed ID: 20727508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of renal failure on drug transport and metabolism.
    Sun H; Frassetto L; Benet LZ
    Pharmacol Ther; 2006 Jan; 109(1-2):1-11. PubMed ID: 16085315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats.
    Naud J; Michaud J; Beauchemin S; Hébert MJ; Roger M; Lefrancois S; Leblond FA; Pichette V
    Drug Metab Dispos; 2011 Aug; 39(8):1363-9. PubMed ID: 21525170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug dosing adjustments in patients with chronic kidney disease.
    Munar MY; Singh H
    Am Fam Physician; 2007 May; 75(10):1487-96. PubMed ID: 17555141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of impaired nonrenal drug clearance in ESRD.
    Nolin TD; Unruh ML
    Semin Dial; 2010; 23(5):482-5. PubMed ID: 21069923
    [No Abstract]   [Full Text] [Related]  

  • 8. Emerging evidence of the impact of kidney disease on drug metabolism and transport.
    Nolin TD; Naud J; Leblond FA; Pichette V
    Clin Pharmacol Ther; 2008 Jun; 83(6):898-903. PubMed ID: 18388866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of chronic renal failure on hepatic drug metabolism and drug disposition.
    Dreisbach AW; Lertora JJ
    Semin Dial; 2003; 16(1):45-50. PubMed ID: 12535300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The roles of transporters and enzymes in hepatic drug processing.
    Liu L; Pang KS
    Drug Metab Dispos; 2005 Jan; 33(1):1-9. PubMed ID: 15466164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics in patients with renal failure.
    Maher JF
    Clin Nephrol; 1984 Jan; 21(1):39-46. PubMed ID: 6368069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a novel method to estimate absolute bioavailability of drugs from oral data.
    Hinderling PH
    Biopharm Drug Dispos; 2003 Jan; 24(1):1-16. PubMed ID: 12516074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state.
    Feng B; LaPerle JL; Chang G; Varma MV
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):939-52. PubMed ID: 20433402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of chronic renal failure on drug metabolism and transport.
    Dreisbach AW; Lertora JJ
    Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1065-74. PubMed ID: 18680441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Individualized PBPK Modeling of Rate Data to Evaluate the Effect of Hemodialysis on Nonrenal Clearance Pathways.
    Franchetti Y; Nolin TD
    J Clin Pharmacol; 2021 Jun; 61(6):769-781. PubMed ID: 33459400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug dosing in chronic kidney disease.
    Gabardi S; Abramson S
    Med Clin North Am; 2005 May; 89(3):649-87. PubMed ID: 15755472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
    Nolin TD; Frye RF; Le P; Sadr H; Naud J; Leblond FA; Pichette V; Himmelfarb J
    J Am Soc Nephrol; 2009 Oct; 20(10):2269-76. PubMed ID: 19696225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450-mediated metabolism in the human gut wall.
    Thelen K; Dressman JB
    J Pharm Pharmacol; 2009 May; 61(5):541-58. PubMed ID: 19405992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effects of CKD on Cytochrome P450-Mediated Drug Metabolism.
    Ladda MA; Goralski KB
    Adv Chronic Kidney Dis; 2016 Mar; 23(2):67-75. PubMed ID: 26979145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.